Abstract
In patients with chronic kidney disease (CKD), vascular calcification is associated with significant morbidity and mortality. The prevalence of vascular calcification increases as glomerular filtration rate (GFR) declines and calcification occurs years earlier in CKD patients than in the general population. The mechanisms of vascular calcification in CKD patients are complex and not completely understood but likely involve non-traditional risk factors, which may be unique to patients with CKD. These unique risk factors may predispose patients to early and more accelerated calcification. Experimental and clinical studies show that disorders in mineral metabolisms including calcium and phosphorus homeostasis initiate and promote vascular calcification in patients with CKD. It is currently unknown if vascular calcification can be prevented or reversed with therapies aimed at maintaining calcium and phosphorus homeostasis. This review focuses on the potential mechanisms by which disordered mineral metabolism may promote vascular calcification in patients with CKD.
Keywords: Vascular calcification, chronic kidney disease, mineral metabolism, phosphorus.
Current Pharmaceutical Design
Title:Vascular Calcification in Chronic Kidney Disease: Role of Disordered Mineral Metabolism
Volume: 20 Issue: 37
Author(s): Shyamal Palit and Jessica Kendrick
Affiliation:
Keywords: Vascular calcification, chronic kidney disease, mineral metabolism, phosphorus.
Abstract: In patients with chronic kidney disease (CKD), vascular calcification is associated with significant morbidity and mortality. The prevalence of vascular calcification increases as glomerular filtration rate (GFR) declines and calcification occurs years earlier in CKD patients than in the general population. The mechanisms of vascular calcification in CKD patients are complex and not completely understood but likely involve non-traditional risk factors, which may be unique to patients with CKD. These unique risk factors may predispose patients to early and more accelerated calcification. Experimental and clinical studies show that disorders in mineral metabolisms including calcium and phosphorus homeostasis initiate and promote vascular calcification in patients with CKD. It is currently unknown if vascular calcification can be prevented or reversed with therapies aimed at maintaining calcium and phosphorus homeostasis. This review focuses on the potential mechanisms by which disordered mineral metabolism may promote vascular calcification in patients with CKD.
Export Options
About this article
Cite this article as:
Palit Shyamal and Kendrick Jessica, Vascular Calcification in Chronic Kidney Disease: Role of Disordered Mineral Metabolism, Current Pharmaceutical Design 2014; 20 (37) . https://dx.doi.org/10.2174/1381612820666140212194926
DOI https://dx.doi.org/10.2174/1381612820666140212194926 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ultrasound Promoted Catalyst-free Procedure for the Synthesis of 1,4- dihydropyridines and Bi-phenyl Derivatives in Water
Current Green Chemistry Editorial [Hot Topic: Matrix Metalloproteinases in Cardiovascular Disease (Guest Editors: N. Papageorgiou & D. Tousoulis)]
Current Topics in Medicinal Chemistry Cannabinoid System as a Potential Target for Drug Development in the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome
Current Vascular Pharmacology Transition in Infant and Young Child Feeding Practices in India
Current Diabetes Reviews Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Vitamin D and Cardio-Metabolic Risk Factors in Overweight Adults: An Overview of the Evidence
Current Pharmaceutical Design Do Human Lipoxygenases have a PDZ Regulatory Domain?
Current Molecular Medicine Matrix Metalloproteinases and Colon Anastomosis Repair: A New Indication for Pharmacological Inhibition?
Mini-Reviews in Medicinal Chemistry Cardiovascular Disease in Primary Sjögren’s Syndrome
Reviews on Recent Clinical Trials Perspectives of Choroidal Neovascularization Therapy
Current Drug Targets Sleep in Pediatric Pulmonary Diseases
Current Respiratory Medicine Reviews Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice
Current Pharmaceutical Design Emerging Concepts for Myocardial Late Gadolinium Enhancement MRI
Current Cardiology Reviews Cardiovascular Effects of Flavonoids
Current Medicinal Chemistry Dehydrogenases/Reductases for the Synthesis of Chiral Pharmaceutical Intermediates
Current Organic Chemistry Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Simultaneous Determination of Amlodipine and Irbesartan in their Pharmaceutical Formulations by Square-Wave Voltammetry
Combinatorial Chemistry & High Throughput Screening The Prevalence of Frailty in Patients Admitted to Hospital with Vertebral Fragility Fractures
Current Rheumatology Reviews The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets